The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation.
 
Arsela Prelaj
No Relationships to Disclose
 
Giuseppe Lo Russo
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Claudia Proto
Consulting or Advisory Role - BMS Brazil; Lilly; Roche
Travel, Accommodations, Expenses - MSD
 
Diego Signorelli
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Roberto Ferrara
No Relationships to Disclose
 
Giulia Galli
No Relationships to Disclose
 
Alessandro De Toma
No Relationships to Disclose
 
Giovanni Randon
No Relationships to Disclose
 
Nicoletta Zilembo
No Relationships to Disclose
 
Benedetta Trevisan
No Relationships to Disclose
 
Michele Montrone
No Relationships to Disclose
 
Vito Longo
No Relationships to Disclose
 
Francesco Pesola
No Relationships to Disclose
 
Niccolò Varesano
No Relationships to Disclose
 
Gabriella Del Bene
No Relationships to Disclose
 
Pamela Pizzutilo
No Relationships to Disclose
 
Domenico Galetta
Consulting or Advisory Role - BMS Brazil
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; GlaxoSmithKline; MSD Oncology; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; MSD Oncology; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Massimo Di Maio
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; MSD
 
Annamaria Catino
No Relationships to Disclose